Literature DB >> 6830740

Visual field survival: the response to timolol therapy in open-angle glaucoma.

W E Sponsel, N L Dallas, L Burbridge.   

Abstract

A simple method for quantifying visual field survival was devised to assess the progress of chronic simple glaucoma in 36 patients treated with timolol maleate over a 3-year period. Routine tonometric monitoring of the intraocular pressure (IOP) was carried out in conjunction with these Goldmann field studies. Statistical analysis revealed that field survival measurement provided a more consistent clinical guide to the progress of glaucoma under treatment than did IOP (p much less than 0.001). Timolol therapy was associated with sustained IOP reductions of 24.3-34.5%, and 63% of those treated who were monitored for field survival showed no significant field loss. The observed relationships of IOP to field survival are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6830740      PMCID: PMC1040023          DOI: 10.1136/bjo.67.4.220

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  2 in total

1.  Diurnal variation of intraocular pressure in primary open-angle glaucoma.

Authors:  Y Kitazawa; T Horie
Journal:  Am J Ophthalmol       Date:  1975-04       Impact factor: 5.258

2.  Monitoring compliance with pilocarpine therapy.

Authors:  S E Norell
Journal:  Am J Ophthalmol       Date:  1981-11       Impact factor: 5.258

  2 in total
  3 in total

1.  Informational content of visual field location in glaucoma.

Authors:  D B Henson; B C Chauhan
Journal:  Doc Ophthalmol       Date:  1985-06-30       Impact factor: 2.379

2.  Referral patterns to an ophthalmic outpatient clinic by general practitioners and ophthalmic opticians and the role of these professionals in screening for ocular disease.

Authors:  R J Harrison; J M Wild; A J Hobley
Journal:  BMJ       Date:  1988-11-05

3.  Association between intraocular pressure and loss of visual field in chronic simple glaucoma.

Authors:  R Vogel; R P Crick; R B Newson; M Shipley; H Blackmore; C J Bulpitt
Journal:  Br J Ophthalmol       Date:  1990-01       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.